Blood Biomarkers in Suicidal Behaviour
- Conditions
- Major Depression
- Interventions
- Other: Blood sample for genetic purpose
- Registration Number
- NCT02855918
- Lead Sponsor
- University Hospital, Montpellier
- Brief Summary
Suicidal behavior (SB) is a major public health problem in France, with more than 10,000 suicides and 220,000 suicide attempts per year.
According to the commonly accepted model for understanding suicidal behavior, individuals who carry a suicidal act when subjected to stress factors (environmental stress, depression, substance ...) are those which have a specific vulnerability.
These vulnerabilities can be considered as clinical parameters (propensity to despair, aggressive and/or impulsive traits), neurobiological parameters (dysfunction of the serotonergic system, ...) and cognitive parameters (taking disadvantageous decision ...). Suicidal vulnerability is partly underpinned by genetic factors. The interest of current researches is to identify biomarkers that will improve the opportunities for early identification of subject with a risk for SB. Numerous scientific studies, including post-mortem studies of the brains of suicide completers, have established a link between dysregulation of the ribonucleic acids editing (RNA) of certain genes, the enzymatic activity of Adenosine deaminases acting on RNA (ADARS) responsible for this edition and suicidal behavior. A prospective study is needed to quantify and qualify in the blood of depressed patients (with or without a history of suicide) and healthy controls, the editing changes and the expression and alteration of the activity of ADARS.
- Detailed Description
Over two years, 600 participants will be recruited:
* 225 subjects with current major depressive episode and an history of suicide attempt (depressed suicide attempters)
* 225 subjects with current major depressive episode but with no personal history of suicide attempt (affective controls)
* 150 subjects with no history of psychopathology whole life (healthy controls)
Each patient will attend a total of 3visits during a follow-up period of 6 months +/- 15 days (inclusion, visit at 3 and 6 months).
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 600
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Blood sample for genetic purpose Blood sample for genetic purpose All the participants performed the same evaluations and blood analysis. The study is composed of 3 groups : * depressed patients with an history of suicide attempt * depressed patients without any history of suicide attempt * healthy controls without any history of psychopathology
- Primary Outcome Measures
Name Time Method Evolution of the modification of the expression of Adenosine deaminases acting on RNA (ADARs) and of the editing profile of phospho-diesterase 8A (PDE8A) At the inclusion visit, 3 months and 6 months after the inclusion Studying ADARs expression and RNA editing of genes associated with SB, including PDE8A and comparison of these results between healthy controls and depressed patients with or without history of SB
- Secondary Outcome Measures
Name Time Method Modification of the expression and RNA editing of Cluster of differentiation 24 (CD24) At the inclusion visit, 3 months and 6 months after the inclusion Comparison between non suicidal and suicidal depressed patients and healthy controls
Modification of the expression and RNA editing of Three prime repair exonuclease 1 (TREX1) At the inclusion visit, 3 months and 6 months after the inclusion Comparison between non suicidal and suicidal depressed patients and healthy controls
Modification of the expression and RNA editing of Interferon stimulated gene 15 (ISG15) At the inclusion visit, 3 months and 6 months after the inclusion Comparison between non suicidal and suicidal depressed patients and healthy controls
Modification of the expression of ADAR1a enzymes At the inclusion visit, 3 months and 6 months after the inclusion Comparison of the profiles of ADARs expression and PDE8A editing between non suicidal and suicidal depressed patients and healthy controls
Modification of the expression and RNA editing of Spindle And Kinetochore Associated protein 2 (SKA2) At the inclusion visit, 3 months and 6 months after the inclusion Comparison between non suicidal and suicidal depressed patients and healthy controls
Modification of the expression of ADAR1b enzymes At the inclusion visit, 3 months and 6 months after the inclusion Comparison of the profiles of ADARs expression and PDE8A editing between non suicidal and suicidal depressed patients and healthy controls
Modification of the expression of ADAR2 enzymes At the inclusion visit, 3 months and 6 months after the inclusion Comparison of the profiles of ADARs expression and PDE8A editing between non suicidal and suicidal depressed patients and healthy controls
Modification of the expression and RNA editing of Spermidine/Spermine N1-Acetyltransferase 1 (SAT1) At the inclusion visit, 3 months and 6 months after the inclusion Comparison between non suicidal and suicidal depressed patients and healthy controls
Modification of the expression and RNA editing of Interleukins (ILs) At the inclusion visit, 3 months and 6 months after the inclusion Comparison between non suicidal and suicidal depressed patients and healthy controls
Modification of the expression and RNA editing of Chemokines (CXCLs) At the inclusion visit, 3 months and 6 months after the inclusion Comparison between non suicidal and suicidal depressed patients and healthy controls
Modification of the expression and RNA editing of Brain derived Neurotrphic factor (BDNF) At the inclusion visit, 3 months and 6 months after the inclusion Comparison between non suicidal and suicidal depressed patients and healthy controls
Modification of the expression and RNA editing of Tumor necrosis factor alpha (TNF alpha) At the inclusion visit, 3 months and 6 months after the inclusion Comparison between non suicidal and suicidal depressed patients and healthy controls
Modification of the expression and RNA editing of Vascular endothelial growth factor (VEGF) At the inclusion visit, 3 months and 6 months after the inclusion Comparison between non suicidal and suicidal depressed patients and healthy controls
Modification of the expression and RNA editing of Hydroxytryptamine receptor 2A (HTR2A) At the inclusion visit, 3 months and 6 months after the inclusion Comparison between non suicidal and suicidal depressed patients and healthy controls
Modification of the expression and RNA editing of insulin-like growth factor protein 7 (IGFB7) At the inclusion visit, 3 months and 6 months after the inclusion Comparison between non suicidal and suicidal depressed patients and healthy controls
Trial Locations
- Locations (1)
University Hospital
🇫🇷Montpêllier, France